Children 12-18 months old were randomized to receive one dose of a conjugate heptavalent
pneumococcal vaccine, two doses of the same vaccine, or one dose of a 23-valent native …

Objective. Prospective studies were conducted to test the hypothesis that infants unlikely to
have serious bacterial infections (SBI) can be accurately identified by low risk criteria. …

A double-blind, randomized study involving 264 toddlers attending day care centers was
conducted to document the effect of a 9-valent pneumococcal conjugate vaccine on the …

Background Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion …

Background Approximately 5.1 million Israelis had been fully immunized against coronavirus
disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA …

Nirsevimab to Prevent RSV Illness in Infants Nirsevimab, a monoclonal antibody targeting
respiratory syncytial virus, protected against RSV-associated hospitalization and severe …

Streptococcus pneumoniae (pneumococcus) is a major cause of worldwide mortality and
morbidity, and to a large extent is vaccine-preventable. Nasopharyngeal carriage of …

The accurate diagnosis of pneumococcal disease has frequently been hampered not only
by the difficulties in obtaining isolates of the organism from patient specimens but also by the …

The rate of Streptococcus pneumoniae carriage among adults was compared with that among
children (age, ⩽6 years) in the same population. Nasopharyngeal culture results for 1300 …

During a 2-year period, 233 infants younger than 3 months were prospectively studied to
determine whether physical examination, white blood cell and band count, and urinalysis could …